Funding CCSVI research is/was a waste of valuable time,money and intellectual energy: Commentary

Barnes MP Bates D Cartlidge NE French JM Shaw DA Hyperbaric oxygen and multiple sclerosis: short-term results of a placebo-controlled, double-blind trial. Lancet 1985;1(8424):297-300.

Barnes MP Bates D Cartlidge NE French JM Shaw DA Hyperbaric oxygen and multiple sclerosis: final results of a placebo-controlled, double-blind trial. J Neurol Neurosurg Psychiatry 1987;50:1402-1406.

International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Sawcer S . Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011 10;476:214-219.

Coles AJ Fox E Vladic A . Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012;78:1069-1078.

Polman CH O’Connor PW Havrdova E . A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899-910.

Cohen JA Barkhof F Comi G . Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415.

van Zuuren EJ Fedorowicz Z Pucci E Jagannath VA Robak EW Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis patients. Cochrane Database Syst Rev 2012 Dec 12;12:CD009903